# Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

> **NCT00962507** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 11 (actual)

## Conditions studied

- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** everolimus
- **DRUG:** panobinostat
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00962507
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2013-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962507, "Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00962507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*